Advancing Brain Organoids from Research Models to Scalable Platforms

Summary

Ottimo Pharma and Asimov discussed strategies for advancing brain organoid research and scaling a dual-paratopic cancer immunotherapy from sequence to patient dosing in under a year during a GEN webinar on manufacturing approaches.